Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …

Multidrug resistance (MDR) is a serious phenomenon employed by cancer cells which
hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR …

Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood …

ATP-binding cassette (ABC) transporters represent one of the largest and oldest families of
membrane proteins in all extant phyla from prokaryotes to humans, which couple the energy …

Objective To monitor trastuzumab resistance and determine the underlying mechanisms for
the limited response rate and rapid emergence of resistance of HER2+ metastatic gastric …

Multidrug resistance (MDR) remains a major clinical obstacle to successful cancer treatment.
Although diverse mechanisms of MDR have been well elucidated, such as dysregulation of …

Accumulating evidence has shown that cancer stem cells (CSCs) have a tumour-initiating
capacity and play crucial roles in tumour metastasis, relapse and chemo/radio-resistance …

Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …

The development of multidrug resistance (MDR) to chemotherapy remains a major
challenge in the treatment of cancer. Numerous mechanisms have been recognized that …

The overexpression of the human ATP-binding cassette (ABC) transporters in cancer cells is
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …